Scolaris Content Display Scolaris Content Display

Corticosteroides orales iniciados por el paciente y por los padres para las exacerbaciones del asma

Collapse all Expand all

References

Referencias de los estudios excluidos de esta revisión

Jump to:

Boushey 2005 {published data only}

Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al. Daily versus as‐needed corticosteroids for mild persistent asthma. New England Journal of Medicine 2005;352(15):1519‐28. [PUBMED: 15829533]CENTRAL

Grant 1995 {published data only}

Grant CC, Duggan AK, DeAngelis C. Independent parental administration of prednisone in acute asthma: a double‐blind, placebo‐controlled, crossover study. Pediatrics 1995;96(2 Pt 1):224‐9. [PUBMED: 7630674]CENTRAL

Milenović 2007 {published data only}

Milenković BA, Stanković IJ, Ilić AM, Petrović VI. Peak expiratory flow‐guided self‐management treatment of asthma in Serbia. Journal of Asthma 2007;44(9):699‐704. CENTRAL

van Der Meer 2009 {published data only}

van der Meer V, Bakker MJ, van den Hout WB, Rabe KF, Sterk PJ, Kievit J, et al. Internet‐based self‐management plus education compared with usual care in asthma: a randomized trial. Annals of Internal Medicine 2009;151(2):110‐20. CENTRAL

Vuillermin 2010 {published data only}

Vuillermin P, Robertson C, Carlin J, Brennan S, Biscan M, South M. Parent‐initiated oral prednisolone for episodes of acute asthma in children aged 5‐13 years. Internal Medicine Journal 2009;39(S5):A159. CENTRAL
Vuillermin P, Robertson C, Carlin J, Brennan S, Biscan M, South M. Parent‐initiated prednisolone for acute asthma in school aged children: a randomised clinical trial. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A6762. CENTRAL
Vuillermin P, Robertson C, Carlin J, Brennan S, Biscan M, South M. Parent‐initiated prednisolone in asthma: a randomised controlled trial. Respirology 2009;14(Suppl 1):A15. CENTRAL
Vuillermin PJ, Robertson CF, Carlin JB, Brennan SL, Biscan MI, South M. Parent initiated prednisolone for acute asthma in children of school age: randomised controlled crossover trial. BMJ 2010;340(7745):c843. CENTRAL

Referencias adicionales

Jump to:

Bai 2007

Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. European Respiratory Journal 2007;30(3):452‐6. [PUBMED: 17537763]

BTS/SIGN 2016

British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. https://www.brit‐thoracic.org.uk/document‐library/clinical‐information/asthma/btssign‐asthma‐guideline‐2016/ (accessed 10 November 2016).

CAMP Research Group 2000

The Childhood Asthma Management Program Research Group. Long‐term effects of budesonide or nedocromil in children with asthma. New England Journal of Medicine 2000;343(15):1054‐63.

Cates 2013

Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD007313.pub3]

Chapman 2010

Chapman KR, Barnes NC, Greening AP, Jones PW, Pedersen S. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax 2010;65(8):747‐52.

Covidence 2016 [Computer program]

Veritas Health Innovation. Covidence systematic review software. Version accessed 18 May 2016. Melbourne: Veritas Health Innovation, 2016.

DoH 2010

Department of Health. Consultation on a strategy for services for chronic obstructive pulmonary disease (COPD) in England. www.gov.uk/government/uploads/system/uploads/attachment_data/file/213840/dh_113279.pdf (accessed 25 November 2015).

Fernandes 2014

Fernandes RM, Oleszczuk M, Woods CR, Rowe BH, Cates CJ, Hartling L. The Cochrane Library and safety of systemic corticosteroids for acute respiratory conditions in children: an overview of reviews. Evidence Based Child Health 2014;9(3):733‐47.

GINA 2016

Global Initiative for Asthma. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2016. ginasthma.org/2016‐gina‐report‐global‐strategy‐for‐asthma‐management‐and‐prevention/ (accessed 27 September 2016).

Global Asthma Report 2014

Global Asthma Network. The Global Asthma Report 2014. Auckland, New Zealand: Global Asthma Network, 2014. www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdf (accessed 20 March 2015).

GRADEpro GDT [Computer program]

GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 2 February 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.

Guyatt 2011

Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck‐Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians. BMJ 2008;336:995‐8.

Haahtela 1994

Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide inpatients with mild asthma. New England Journal of Medicine 1994;331(11):700‐5.

Higgins 2011

Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Kelly 2008

Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC. Effect of long‐term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics 2008;122:e53–61.

Moher 2009

Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]

NACA 2015

National Asthma Council Australia. Guide to systemic corticosteroids. www.asthmahandbook.org.au/resources/medicines‐guide/systemic‐corticosteroids (accessed 25 November 2015).

NICE 2007

National Institute for Health and Care Excellence. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years. TA131. www.nice.org.uk/guidance/ta131 (accessed 23 March 2015).

NICE 2010

National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. www.nice.org.uk/guidance/cg101/chapter/1‐Guidance#management‐of‐exacerbations‐of‐copd (accessed 25 November 2015).

NICE 2013

National Institute for Health and Care Excellence. Quality standard for asthma [QS 25]. www.nice.org.uk/guidance/qs25 (accessed 23 March 2015).

Petsky 2012

Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, et al. A systematic review and meta‐analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67(3):199‐208.

Rang 2015

Rang HP, Ritter JM, Flower RJ, Henderson G. Rang and Dale's Pharmacology. 8th Edition. Churchill and Livingstone, 2015.

RevMan 2014 [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Rowe 2007

Rowe BH, Spooner C, Ducharme F, Bretzlaff J, Bota G. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD000195.pub2]

Streetman 2002

Streetman DD, Bhatt‐Mehta V, Johnson CE. Management of acute severe asthma in children. Annals of Pharmacotherapy 2002;36:1249‐60.

Vuillermin 2006

Vuillermin P, South M, Robertson C. Parent‐initiated oral corticosteroid therapy for intermittent wheezing illnesses in children. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD005311.pub2]

Vuillermin 2007

Vuillermin PJ, South M, Carlin JB, Biscan MI, Brennan SL, Robertson CF. Parent‐initiated oral corticosteroid therapy for acute asthma: a survey of current practice. Journal of Paediatrics and Child Health 2007;43(6):443‐5.

Weinstein 2015

Weinstein AG. Improving adherence to asthma therapies. Current Opinion in Pulmonary Medicine 2015;21(1):86‐94.

Referencias de otras versiones publicadas de esta revisión

Jump to:

Ganaie 2016

Ganaie MB, Munavvar M, Gordon M, Evans DJW. Patient‐ and parent‐initiated oral steroids for asthma exacerbations. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD012195]

Characteristics of studies

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Boushey 2005

OCS was not part of the randomised treatment

Grant 1995

Cross‐over design

Milenović 2007

OCS was administered as part of asthma action plan (i.e. co‐intervention), which was part of randomised treatment

van Der Meer 2009

OCS could be optionally administered as part of asthma action plan, which was part of randomised treatment

Vuillermin 2010

Cross‐over design

OCS = oral corticosteroids.

Study flow diagram.
Figures and Tables -
Figure 1

Study flow diagram.

Navigate to figure in ReviewOpen in new tab
Summary of findings for the main comparison. Summary of findings: patient‐initiated steroids

Patient‐initiated steroids compared with placebo/normal care/alternative active treatment for asthma

Patient or population: adults aged 18 years or older with asthma

Settings: outpatient

Intervention: patient‐initiated oral corticosteroids

Comparison: placebo/normal care/alternative active treatment

Outcomes

Number of participants
(studies)

Comments

Hospital admissions for asthma

0 (0 studies)

No studies met the inclusion criteria for this review

Asthma control (validated scales)

0 (0 studies)

Serious adverse events (all cause)

0 (0 studies)

Unscheduled visit to a healthcare provider

0 (0 studies)

Health‐related quality of life (validated scales)

0 (0 studies)

Days lost of study/work

0 (0 studies)

Adverse events (all cause)

0 (0 studies)

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: We are very uncertain about the estimate

Figures and Tables -
Summary of findings for the main comparison. Summary of findings: patient‐initiated steroids
Navigate to table in Review
Summary of findings 2. Summary of findings: parent‐initiated steroids

Parent‐initiated steroids compared with placebo/normal care/alternative active treatment for asthma

Patient or population: children aged 5 years or older with asthma

Settings: outpatient

Intervention: parent‐initiated oral corticosteroids

Comparison: placebo/normal care/alternative active treatment

Outcomes

Number of participants
(studies)

Comments

Hospital admissions for asthma

0 (0 studies)

No studies met the inclusion criteria for this review

Asthma control (validated scales)

0 (0 studies)

Serious adverse events (all cause)

0 (0 studies)

Unscheduled visit to a healthcare provider

0 (0 studies)

Health‐related quality of life (validated scales)

0 (0 studies)

Days off school

0 (0 studies)

Adverse events (all cause)

0 (0 studies)

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: We are very uncertain about the estimate

Figures and Tables -
Summary of findings 2. Summary of findings: parent‐initiated steroids
Navigate to table in Review